12:00 PM EST - Prometic Life Sciences Inc. : Announced the publication in the American Journal of Pathology, the official journal of the American Society of Investigational Pathology, of the novel antifibrotic mechanism of action of its small molecule lead drug candidate, PBI-4050. The paper entitled "A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84" documents the discovery of an antifibrotic pathway involving these two receptors. Prometic Life Sciences Inc.
shares T.PLI are trading up $0.04 at $1.55.
